Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

I-Mab Starts Second China Trial of CD38 Antibody for Multiple Myeloma

publication date: Apr 30, 2019

I-Mab Biopharma of Shanghai has begun a randomized multi-center Phase III clinical trial in Taiwan and China to evaluate a human CD38 antibody in combination with Revlimid in patients with relapsed or refractory multiple myeloma. Revlimid is commonly used to treat multiple myeloma. In 2017, I-Mab in-licensed rights to the CD38 antibody from MorphoSys AG in a $120 million agreement. One month ago, I-Mab announced it was starting Taiwan Phase II trials of the CD38 antibody as a single agent in multiple myeloma. More details....

Stock Symbol: (FSE/NSDQ: MOR)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital